Wild, C. (2005): . HTA-Newsletter 40: p. 4.

[thumbnail of HTA-Newsletter 40]
PDF (HTA-Newsletter 40) - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader

Official URL: http://hw.oeaw.ac.at/ita/hta-newsletter?frames=yes

Item Type:HTA Newsletter Item
Keywords:MabThera®, rituximab, monoclonal antibody, non-Hodgkin’s lymphoma (NHL), drug therapy, effectiveness, approval
Subjects:WH Hemic and lymphatic systems
QW Microbiology. Immunology
Related URLs:
References:1. Ontario Cancer Care/CA 2005: Evidence Based Cancer Guidelines Rituximab. URL: http://www.cancercare.on.ca/pdf/pebc6-8s.pdf.

2. BCBS/USA 2002: Rituximab for treatment of intermediate and aggressive B-cell non-Hodgkin’s lymphomas. URL: http://www.bcbs.com/tec/vol17/17_03.html.

3. NHSC/GB 2002: Rituximab for aggressive B-cell lymphoma. URL: http://pcpoh.bham.ac.uk/publichealth/horizon/PDF_files/2002reports/Rituximab.pdf.

4. NICE/GB 2003: Rituximab for aggressive B-cell lymphoma. URL: http://www.nice.org.uk/cat.asp?c=86763.

5. NHSC/GB 2004: Rituximab for 1st line lowgrade non-Hodgkin’s lymphoma – horizon scanning review. URL: http://www.pcpoh.bham.ac.uk/publichealth/horizon/PDF_files/2004reports/Rituximab.pdf.

6. EMEA 1998: Rituximab. URL: http://www.emea.eu.int/humandocs/PDFs/EPAR/Mabthera/025998en1.pdf.
Deposited on:25 Feb 2008 17:26
Last Modified:15 Jul 2020 17:36

Repository Staff Only: item control page